Another bluebird exec jumps ship as questions swirl over gene therapies and imminent split
On the same day that their former COO found a new job steering the ship at a biotech focused on engineering B cells, bluebird bio said goodbye to another C-suite executive.
David Davidson, bluebird’s longtime chief medical officer, is jumping ship as questions continue to swirl about the safety of their gene therapy programs, the company revealed in an SEC filing Tuesday. Davidson will leave effective April 16, and will work as a consultant for six months as bluebird transitions to a new CMO. He’ll also receive 12 months of severance starting at the end of April.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.